platinum investigator choice
Sponsor Merck & CO INC. · listed as MRK
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
platinum investigator choice is a clinical-stage drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 28, 2027 (day precision, medium confidence), tied to trial NCT04624204. The asset is in Phase 3 and currently active not recruiting, studied in Small Cell Lung Cancer.
Next catalyst
Event typeREADOUT
Expected date2027-10-28
As disclosedOct 28, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT04624204
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorMerck Sharp & Dohme LLC
Listed asMRK
Condition(s)Small Cell Lung Cancer
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More MRK catalysts